MorphoSys AG (MorphoSys AG) 12-1 Month Momentum % : 237.29% (As of Apr. 25, 2024)

View and export this data going back to 2018. Start your Free Trial

What is MorphoSys AG 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-25), MorphoSys AG's 12-1 Month Momentum % is 237.29%.

The industry rank for MorphoSys AG's 12-1 Month Momentum % or its related term are showing as below:

MOR's 12-1 Month Momentum % is ranked better than
97.84% of 1484 companies
in the Biotechnology industry
Industry Median: -22.18 vs MOR: 237.29

Competitive Comparison of MorphoSys AG's 12-1 Month Momentum %

For the Biotechnology subindustry, MorphoSys AG's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's 12-1 Month Momentum % falls into.

MorphoSys AG (NAS:MOR) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MorphoSys AG (NAS:MOR) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

MorphoSys AG 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (MorphoSys AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (NAS:MOR) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

MPSYF:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.